Serina Therapeutics, Inc. (SER) - 2024 Annual Report Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2024. Serina Therapeutics, Inc. is a clinical-stage biotechnology company developing a pipeline of drug candidates for neurological diseases, primarily Parkinson's disease, using its proprietary POZ (poly(2-oxazoline)) polymer platform. The company completed a reverse recapitalization merger with AgeX Therapeutics, Inc. on March 26, 2024, becoming a publicly traded entity on the NYSE American under the symbol "SER". The company has no approved products and relies on external funding and licensing agreements to finance operations.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenues | $56,000 | $3,153,000 |
| Net Loss | $(11,207,000) | $5,269,000 (Net Income) |
| Operating Expenses | $17,104,000 | $6,282,000 |
| Cash and Cash Equivalents (Year End) | $3,672,000 | $7,619,000 |
| Accumulated Deficit | $(44,318,000) | $(33,177,000) |
| Warrant Liability | $3,582,000 | $0 |
Note: 2023 Net Income was driven by non-cash fair value adjustments on convertible notes and warrants. 2024 Net Loss includes significant operating expenses and fair value losses on convertible notes, partially offset by gains on warrant liabilities.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue dropped from $3.15 million in 2023 to $56,000 in 2024. The 2023 figure included a one-time $3.0 million upfront payment from a non-exclusive license agreement with Pfizer. No similar milestone or upfront payments were recognized in 2024.
- Expense Surge: Operating expenses increased 172% to $17.1 million. Research and Development (R&D) expenses rose to $7.5 million (from $2.4 million), driven by the advancement of the lead candidate SER 252. General and Administrative (G&A) expenses rose to $9.6 million (from $3.9 million) due to public company costs, legal fees, and stock-based compensation.
- Merger Impact: The March 2024 merger resulted in the conversion of preferred stock and notes into common equity, the issuance of Post-Merger Warrants, and the assumption of certain liabilities. The company also sold its subsidiary UniverXome to Juvenescence in December 2024, extinguishing approximately $11.3 million of secured debt.
- Financing Activity: The company raised capital through the exercise of Post-Merger Warrants by Juvenescence ($5.0 million) and a stock purchase agreement ($5.0 million received in 2024, with a second tranche of $5.0 million received in January 2025).
Guidance, Outlook, and Risks
Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. As of December 31, 2024, cash on hand ($3.7 million) plus the $5.0 million received from Juvenescence in January 2025 is not expected to be sufficient to fund operations through calendar year 2025. Additional financing is required to continue development.
Development Outlook:
- SER 252 (POZ-apomorphine): The lead candidate for advanced Parkinson's disease is in IND-enabling preclinical studies, anticipated to complete in Q2 2025. Phase I clinical trials are targeted for the second half of 2025.
- SER 214 (POZ-rotigotine): Completed Phase Ia; not being advanced internally but may be out-licensed.
- POZ-Lipids: Advancing preclinical research for LNP vaccines as a PEG alternative; seeking licensing partnerships.
Key Risks:
- Liquidity: Immediate need for additional capital to fund operations and clinical trials.
- Internal Controls: The company identified material weaknesses in internal control over financial reporting, citing insufficient qualified accounting personnel and reliance on manual processes.
- Concentration of Ownership: Juvenescence Limited owns approximately 40.5% of outstanding common stock and holds significant warrants, exerting substantial influence over corporate matters.
- Regulatory Approval: No products are approved; success depends on clinical trial results and FDA approval, which are uncertain.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of current cash balances and the timing of the second tranche of the Juvenescence stock purchase ($5.0 million) to confirm operational runway beyond 2025.
- Debt Extinguishment: Confirm the final accounting treatment and impact of the UniverXome sale to Juvenescence on the balance sheet and future debt obligations.
- Warrant Liability Volatility: Monitor the fair value of the $3.6 million warrant liability, as fluctuations will impact reported net income/loss without affecting cash flow.
- Internal Control Remediation: Review progress on the remediation plan for material weaknesses in internal controls to ensure future financial reporting reliability.
- SER 252 Timeline: Track the completion of IND-enabling studies and the submission of the Investigational New Drug (IND) application scheduled for 2025.